In patients with COVID-19, a broad range of autoantibodies, including ANA, anti-Ro/SSA, rheumatoid factor, lupus anticoagulant, and antibodies against type I interferons, have been identified [77], and an increased risk of developing autoimmune diseases such as rheumatoid arthritis, pemphigus, or pemphigoid has been reported [78]. Here, TRIM21 is linked to COVID-19.